Similarly, Feng et al.'s work on the role of exosomal ITGB6 in activating CAFs and ECM remodeling shed light on the pathways governing tumor dormancy and recurrence in LUAD, suggesting that targeted interventions targeting the ITGB6-KLF10-TGF-β axis are novel therapeutic strategies [181]. Here, ITGB6 is linked to neoplasm.